Collegium Pharmaceutical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Collegium Pharmaceutical generated cash of $274,749,000, which is more than the previous year. Cash used in financing activities reached the amount of -$140,178,000 last year. Net change in cash is therefore $63,759,000.
Cash Flow
| 2014 | -17.94M | -8K | 12.03M |
|---|---|---|---|
| 2015 | -21.56M | -362K | 115.99M |
| 2016 | -75.05M | -2.97M | 135.55M |
| 2017 | -67.01M | -990K | 33.48M |
| 2018 | 169.39M | -24.35M | -117.19M |
| 2019 | 27.78M | -6.43M | 2.04M |
| 2020 | 93.94M | -373.77M | 286.47M |
| 2021 | 103.55M | -1.94M | -89.30M |
| 2022 | 124.23M | -573.69M | 436.72M |
| 2023 | 274.74M | -70.81M | -140.17M |
COLL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 176.23M | 188.97M | 176.66M | 170.01M | 146.63M | 118.79M | 153.22M | 95.69M | 1.63M | 7.55M |
Operating activities | ||||||||||
Net income | 48.15M | -25.00M | 71.51M | 26.75M | -22.72M | -39.12M | -74.86M | -94.17M | -27.25M | -17.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 149.25M | 138.93M | 68.91M | 61.55M | 15.48M | 110.90M | 594K | 655K | 171K | 187K |
Stock-based compensation expense | 27.13M | 22.87M | 24.25M | 21.91M | 16.52M | 13.77M | 7.94M | 5.78M | 2.20M | 22K |
| Deferred income tax benefit | 27.13M | 22.87M | 24.25M | 21.91M | 16.52M | 13.77M | 7.94M | 5.78M | 2.20M | 22K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3.59M | -21.78M | -22.52M | -10.36M | 4.99M | -68.23M | -7.84M | -2.12M | 0 | 0 |
Inventories | 14.16M | 48.27M | -2.29M | -8.27M | -1.82M | 219K | -497K | -1.31M | 0 | 0 |
Accounts payable | 5.06M | -707K | -5.82M | 3.76M | -5.90M | 6.46M | -3.42M | 5.56M | 1.29M | 990K |
Cash generated by operating activities | 274.74M | 124.23M | 103.55M | 93.94M | 27.78M | 169.39M | -67.01M | -75.05M | -21.56M | -17.94M |
Investing activities | ||||||||||
Purchases Of Investments | -92.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -461K | -1.62M | -1.94M | -373.77M | -6.43M | -24.35M | -990K | -2.97M | -362K | -8K |
Acquisitions Net | 0 | -572.06M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -70.81M | -573.69M | -1.94M | -373.77M | -6.43M | -24.35M | -990K | -2.97M | -362K | -8K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 12.70M | 7.33M | 2.86M | -30K | 34.33M | 0 | 72.02M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -24.57M | 0 |
Repurchases of common stock | -75M | -14.06M | -52.01M | -2.25M | -822K | -30K | 0 | 0 | 0 | 0 |
Repayments of term debt | -65.91M | 442.68M | -50M | -289.32M | 0 | -10.02M | -2.66M | -2.66M | -1.34M | -90K |
Cash used in financing activities | -140.17M | 436.72M | -89.30M | 286.47M | 2.04M | -117.19M | 33.48M | 135.55M | 115.99M | 12.03M |
Net Change In Cash | 63.75M | -12.73M | 12.31M | 6.64M | 23.38M | 27.83M | -34.52M | 57.52M | 94.06M | -5.91M |
Cash at end of period | 239.99M | 176.23M | 188.97M | 176.66M | 170.01M | 146.63M | 118.69M | 153.22M | 95.69M | 1.63M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |